NASDAQ:BGNE BeiGene - BGNE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BeiGene, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $247.67 +2.49 (+1.02%) (As of 02/7/2023 11:58 AM ET) Add Compare Share Share Today's Range$247.35▼$252.0350-Day Range$179.86▼$274.5052-Week Range$118.18▼$280.62Volume45,647 shsAverage Volume264,138 shsMarket Capitalization$25.75 billionP/E RatioN/ADividend YieldN/APrice Target$286.43 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media BeiGene MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside15.8% Upside$286.43 Price TargetShort InterestHealthy1.85% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 5 Articles This WeekInsider TradingSelling Shares$9.41 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($17.64) to ($12.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.81 out of 5 starsMedical Sector674th out of 1,027 stocksPharmaceutical Preparations Industry330th out of 500 stocks 2.5 Analyst's Opinion Consensus RatingBeiGene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $286.43, BeiGene has a forecasted upside of 15.8% from its current price of $247.35.Amount of Analyst CoverageBeiGene has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.85% of the outstanding shares of BeiGene have been sold short.Short Interest Ratio / Days to CoverBeiGene has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in BeiGene has recently decreased by 6.34%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBeiGene does not currently pay a dividend.Dividend GrowthBeiGene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BGNE. Previous Next 1.9 News and Social Media Coverage News SentimentBeiGene has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for BeiGene this week, compared to 5 articles on an average week.Search Interest8 people have searched for BGNE on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added BeiGene to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BeiGene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,407,504.00 in company stock.Percentage Held by InsidersOnly 7.50% of the stock of BeiGene is held by insiders.Percentage Held by Institutions51.43% of the stock of BeiGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BeiGene are expected to grow in the coming year, from ($17.64) to ($12.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BeiGene is -11.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BeiGene is -11.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeiGene has a P/B Ratio of 4.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BeiGene (NASDAQ:BGNE) StockBeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.Read More Receive BGNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter. Email Address BGNE Stock News HeadlinesFebruary 6, 2023 | finance.yahoo.comQuebec becomes first province to cover PrBRUKINSA® (zanubrutinib) for the Treatment of Waldenström's macroglobulinemiaFebruary 3, 2023 | finance.yahoo.comIs There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 40% Undervaluation?February 7, 2023 | PressReach (Ad)Is This Stock On Your RadarThis stock is positioned like its peers that cashed out.February 1, 2023 | americanbankingnews.comBeiGene, Ltd. (NASDAQ:BGNE) Short Interest UpdateJanuary 28, 2023 | americanbankingnews.comAnalysts Set BeiGene, Ltd. (NASDAQ:BGNE) PT at $286.43January 20, 2023 | finance.yahoo.comFDA Approves BeiGene's Brukinsa For Chronic Lymphocytic LeukemiaJanuary 19, 2023 | finance.yahoo.comBRUKINSA® Approved in the U.S. for Chronic Lymphocytic LeukemiaJanuary 19, 2023 | finance.yahoo.comBRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRAFebruary 7, 2023 | Investing Trends (Ad)Move Over Lithium – 220 Pounds of Graphite In Every EV BatteryInvestors constantly hear that lithium is the key to powering our transition to electric vehicles and clean energy. Truth is, switching from gas-powered isn't possible without massive amounts of graphite. But America hasn't produced any graphite since the 1950s. Now, a little-known exploration company has defined America's largest high-quality graphite deposit near Nome, Alaska.January 18, 2023 | finance.yahoo.comBeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug ListJanuary 17, 2023 | finance.yahoo.comBeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers SymposiumJanuary 16, 2023 | finance.yahoo.comWhat Makes BeiGene, Ltd. (BGNE) a Good Fit for 'Trend Investing'January 4, 2023 | finance.yahoo.comBeiGene to Present at the J.P. Morgan 41st Annual Healthcare ConferenceDecember 30, 2022 | finance.yahoo.comBeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor TislelizumabDecember 13, 2022 | finance.yahoo.comBeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASHDecember 13, 2022 | msn.comBeiGene Earnings Perspective: Return On Capital EmployedDecember 13, 2022 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About BeiGeneDecember 8, 2022 | finance.yahoo.comPhanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 in combination with TislelizumabDecember 8, 2022 | finance.yahoo.comPhanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 in combination with TislelizumabDecember 1, 2022 | finance.yahoo.comWhy Shares of BeiGene Were Up WednesdayNovember 27, 2022 | finance.yahoo.comIn the wake of BeiGene, Ltd.'s (NASDAQ:BGNE) latest US$2.9b market cap drop, institutional owners may be forced to take severe actionsNovember 25, 2022 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on BeiGene (BGNE)November 22, 2022 | finance.yahoo.comBeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022November 17, 2022 | finance.yahoo.comBeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)November 10, 2022 | finance.yahoo.comBeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood CancersNovember 4, 2022 | finance.yahoo.comBeiGene to Present at Upcoming Investor ConferencesNovember 3, 2022 | finance.yahoo.comBeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH MeetingSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BGNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter. Email Address BGNE Company Calendar Last Earnings11/09/2022Today2/07/2023Next Earnings (Estimated)2/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BGNE CUSIPN/A CIK1651308 Webwww.beigene.com Phone(345) 949-4123FaxN/AEmployees8,200Year Founded2010Price Target and Rating Average Stock Price Forecast$286.43 High Stock Price Forecast$350.00 Low Stock Price Forecast$213.00 Forecasted Upside/Downside+15.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($21.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,413,350,000.00 Net Margins-171.94% Pretax Margin-169.38% Return on Equity-38.92% Return on Assets-27.93% Debt Debt-to-Equity Ratio0.04 Current Ratio4.07 Quick Ratio3.87 Sales & Book Value Annual Sales$1.18 billion Price / Sales21.89 Cash FlowN/A Price / Cash FlowN/A Book Value$60.95 per share Price / Book4.06Miscellaneous Outstanding Shares103,960,000Free Float96,159,000Market Cap$25.75 billion OptionableOptionable Beta0.72 Social Links Key ExecutivesJohn V. OylerChairman & Chief Executive OfficerXiao Bin WuPresident & Chief Operating OfficerJulia WangChief Financial & Accounting OfficerChristiane LangerSenior Vice President-Global Medical AffairsMark LanasaChief Medical OfficerKey CompetitorsGenmab A/SNASDAQ:GMABAlnylam PharmaceuticalsNASDAQ:ALNYHorizon Therapeutics PublicNASDAQ:HZNPBioMarin PharmaceuticalNASDAQ:BMRNViatrisNASDAQ:VTRSView All CompetitorsInsiders & InstitutionsHandelsbanken Fonder ABBought 3,266 shares on 2/7/2023Ownership: 0.024%TD Asset Management IncBought 954 shares on 2/7/2023Ownership: 0.017%Oppenheimer Asset Management Inc.Sold 653 shares on 2/7/2023Ownership: 0.011%Shell Asset Management Co.Sold 1,238 shares on 2/7/2023Ownership: 0.005%NINE MASTS CAPITAL LtdBought 3,812 shares on 2/7/2023Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions BGNE Stock - Frequently Asked Questions Should I buy or sell BeiGene stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BGNE shares. View BGNE analyst ratings or view top-rated stocks. What is BeiGene's stock price forecast for 2023? 5 Wall Street analysts have issued twelve-month price objectives for BeiGene's shares. Their BGNE share price forecasts range from $213.00 to $350.00. On average, they predict the company's stock price to reach $286.43 in the next year. This suggests a possible upside of 16.8% from the stock's current price. View analysts price targets for BGNE or view top-rated stocks among Wall Street analysts. How have BGNE shares performed in 2023? BeiGene's stock was trading at $219.94 at the beginning of 2023. Since then, BGNE shares have increased by 11.5% and is now trading at $245.18. View the best growth stocks for 2023 here. Are investors shorting BeiGene? BeiGene saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 1,920,000 shares, a decline of 6.3% from the December 31st total of 2,050,000 shares. Based on an average daily volume of 268,800 shares, the days-to-cover ratio is presently 7.1 days. View BeiGene's Short Interest. When is BeiGene's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023. View our BGNE earnings forecast. How were BeiGene's earnings last quarter? BeiGene, Ltd. (NASDAQ:BGNE) released its quarterly earnings data on Wednesday, November, 9th. The company reported ($5.39) earnings per share for the quarter, missing the consensus estimate of ($4.02) by $1.37. The business earned $387.63 million during the quarter, compared to the consensus estimate of $360.25 million. BeiGene had a negative trailing twelve-month return on equity of 38.92% and a negative net margin of 171.94%. What is John V. Oyler's approval rating as BeiGene's CEO? 58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend. What other stocks do shareholders of BeiGene own? Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO). When did BeiGene IPO? (BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager. What is BeiGene's stock symbol? BeiGene trades on the NASDAQ under the ticker symbol "BGNE." Who are BeiGene's major shareholders? BeiGene's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.28%), M&G Investment Management Ltd. (0.12%), DekaBank Deutsche Girozentrale (0.03%), SG Americas Securities LLC (0.02%), Sumitomo Mitsui Trust Holdings Inc. (0.02%) and Asset Management One Co. Ltd. (0.02%). Insiders that own company stock include Amgen Inc, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang. View institutional ownership trends. How do I buy shares of BeiGene? Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BeiGene's stock price today? One share of BGNE stock can currently be purchased for approximately $245.18. How much money does BeiGene make? BeiGene (NASDAQ:BGNE) has a market capitalization of $25.49 billion and generates $1.18 billion in revenue each year. The company earns $-1,413,350,000.00 in net income (profit) each year or ($21.35) on an earnings per share basis. How many employees does BeiGene have? The company employs 8,200 workers across the globe. How can I contact BeiGene? BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The official website for the company is www.beigene.com. The company can be reached via phone at (345) 949-4123 or via email at ir@beigene.com. This page (NASDAQ:BGNE) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.